Teva Pharmaceutical Industries (TEVA) EBIAT (2016 - 2025)
Historic EBIAT for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $481.0 million.
- Teva Pharmaceutical Industries' EBIAT rose 27490.91% to $481.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4 billion, marking a year-over-year increase of 17072.32%. This contributed to the annual value of $1.4 billion for FY2025, which is 17238.39% up from last year.
- According to the latest figures from Q4 2025, Teva Pharmaceutical Industries' EBIAT is $481.0 million, which was up 27490.91% from $434.0 million recorded in Q3 2025.
- Teva Pharmaceutical Industries' 5-year EBIAT high stood at $1.7 billion for Q4 2023, and its period low was -$1.3 billion during Q4 2022.
- In the last 5 years, Teva Pharmaceutical Industries' EBIAT had a median value of -$44.5 million in 2021 and averaged -$101.0 million.
- Its EBIAT has fluctuated over the past 5 years, first crashed by 123690.48% in 2022, then soared by 27490.91% in 2025.
- Teva Pharmaceutical Industries' EBIAT (Quarter) stood at -$152.0 million in 2021, then tumbled by 776.97% to -$1.3 billion in 2022, then soared by 227.31% to $1.7 billion in 2023, then plummeted by 116.21% to -$275.0 million in 2024, then soared by 274.91% to $481.0 million in 2025.
- Its EBIAT was $481.0 million in Q4 2025, compared to $434.0 million in Q3 2025 and $283.0 million in Q2 2025.